Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 49 |
| Updated: | 5/5/2014 |
| Start Date: | May 2013 |
| End Date: | September 2013 |
| Contact: | For participation information at a USA site use a phone number below. For site information outside the USA please email: |
| Email: | Clinical.Trials@bms.com |
Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects
The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of
the CYP3A4 Probe Midazolam.
the CYP3A4 Probe Midazolam.
Inclusion Criteria:
- Healthy male and female subjects aged 18 to 49 years, with BMI of 18-32 kg/m²
- Women who are not of childbearing potential
Exclusion Criteria:
- Women of childbearing potential
- Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable
method of birth control.
- Gastrointestinal disease that may impact the absorption of study drug
- History of any chronic respiratory disease (asthma, COPD)
We found this trial at
1
site
Click here to add this to my saved trials
